Prevention and treatment of alzheimer'S disease through electromagnetic field exposure

US9238149B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9238149-B2
Application numberUS-201113230415-A
CountryUS
Kind codeB2
Filing dateSep 12, 2011
Priority dateMar 11, 2009
Publication dateJan 19, 2016
Grant dateJan 19, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention includes a method of treating and preventing a neurological disorder, such as Alzheimer's Disease, in a subject in need thereof by positioning an electromagnetic field emitting source proximal to the subject and exposing the subject to an electromagnetic field having a predetermined frequency for a predetermined absorption period. Preferably, each individual treatment (comprising exposure to the predetermined frequency for the predetermined absorption period) is continued at a predetermined schedule (preferably daily) for a predetermined treatment period. The predetermined frequency, according to a preferred embodiment, is about 918 MHz with a specific absorption rate (SAR) of about 0.25 W/kg+/−2 dB. The predetermined absorption period of this preferred embodiment is about one hour. The treatment period is long-term, being greater than about 6 months and preferably between about 7 and 9 months.

First claim

Opening claim text (preview).

What is claimed is: 1. A method of treating and preventing a symptom associated with Alzheimer's Disease in a subject, wherein said symptom is associated with amyloid deposit or cognitive ability, comprising: positioning an electromagnetic field emitting source proximal to the subject; exposing the subject to electromagnetic treatment by an electromagnetic field generated by a digital signal generator, said electromagnetic field having a predetermined frequency for a predetermined absorption period, said predetermined frequency having a range of about 902 MHz to about 928 MHz; continuing exposure to the subject for the predetermined absorption period for a predetermined treatment period greater that about three (3) days; and reversing or reducing cognitive impairment or amyloid aggregation in said subject, decreasing a rate of amyloid deposition, or enhancing cognitive performance in said subject based on said step of continuing exposure for greater than about three (3) days. 2. The method of claim 1 , wherein the predetermined frequency is about 918 MHz. 3. The method of claim 1 , wherein the electromagnetic field has a specific absorption rate of about 0.25 W/kg to about 1.6 W/kg. 4. The method of claim 1 , wherein the predetermined absorption period is about one hour twice daily. 5. The method of claim 1 , wherein the predetermined treatment period is greater than about 4 months. 6. The method of claim 1 , wherein the predetermined treatment period is between about 7 and 9 months. 7. The method of claim 1 , wherein an enhancement of said cognitive performance in said subject is indicated by an enhancement of working or short-term memory performance of said subject. 8. A method of treating and preventing an amyloid-related neurological disorder in a subject thereof, comprising: positioning an electromagnetic field emitting source proximal to the subject; exposing the subject to electromagnetic treatment by an electromagnetic field generated by a digital signal generator, said electromagnetic field having a predetermined frequency for a predetermined absorption period, said predetermined frequency having a range of about 902 MHz to about 928 MHz; continuing exposure to the subject for the predetermined absorption period for a predetermined treatment period greater than about three (3) days; and reversing or reducing cognitive impairment or amyloid aggregation in said subject, decreasing a rate of amyloid deposition, or enhancing cognitive performance in said subject based on said step of continuing exposure for greater than about three (3) days. 9. The method of claim 8 , wherein the predetermined frequency is about 918 MHz. 10. The method of claim 8 , wherein the electromagnetic field has a specific absorption rate of about 0.25 W/kg to about 1.6 W/kg. 11. The method of claim 8 , wherein the predetermined absorption period is about one hour twice daily. 12. The method of claim 8 , wherein the predetermined treatment period is greater than about 4 months. 13. The method of claim 8 , wherein the predetermined treatment period is between about 7 and 9 months. 14. The method of claim 8 , wherein an enhancement of said cognitive performance in said subject is indicated by an enhancement of working or short-term memory performance of said subject. 15. A method of enhancing cognitive function in a normal, cognitively unimpaired subject, comprising: positioning an electromagnetic field emitting source proximal to the subject; exposing the subject to electromagnetic treatment by an electromagnetic field generated by a digital signal generator, said electromagnetic field having a predetermined frequency for a predetermined absorption period, said predetermined frequency having a range of about 902 MHz to about 928 MHz; continuing exposure to the subject for the predetermined absorption period for a predetermined treatment period; and enhancing cognitive performance of said subject based on said step of continuing exposure for said predetermined treatment period, wherein said enhancing cognitive performance of said subject includes enhancing working memory performance of said subject. 16. The method of claim 15 , wherein the predetermined frequency is about 918 MHz. 17. The method of claim 15 , wherein the electromagnetic field has a specific absorption rate of about 0.25 W/kg to about 1.6 W/kg. 18. The method of claim 15 , wherein the predetermined absorption period is about one hour twice daily. 19. The method of claim 15 , wherein the predetermined treatment period is greater than about three (3) days. 20. The method of claim 15 , wherein the predetermined treatment period is greater than about four (4) months.

Assignees

Inventors

Classifications

  • A61N5/02Primary

    using microwaves · CPC title

  • using magnetic fields produced by coils, including single turn loops or electromagnets (A61N2/12 takes precedence) · CPC title

  • for magnetic stimulation of nerve tissue · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9238149B2 cover?
The invention includes a method of treating and preventing a neurological disorder, such as Alzheimer's Disease, in a subject in need thereof by positioning an electromagnetic field emitting source proximal to the subject and exposing the subject to an electromagnetic field having a predetermined frequency for a predetermined absorption period. Preferably, each individual treatment (comprising …
Who is the assignee on this patent?
Arendash Gary W, Cao Chuanhai, Tan Jun, and 1 more
What technology area does this patent fall under?
Primary CPC classification A61N5/02. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Jan 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).